Borre, EthanMyers, EvanDubno, JudyO’Donoghue, GerardDiab, MohamedEmmett, SusanSaunders, JamesDer, CarolinaMcMahon, CatherineYounis, DanahFrancis, HowardTucci, DebaraWilson, BlakeOgbuoji, OsonduSanders, Gillian2023-04-252023-04-252022Borre ED, Myers ER, Dubno JR, O'Donoghue GM, Diab MM, Emmett SD, Saunders JE, Der C, McMahon CM, Younis D, Francis HW, Tucci DL, Wilson BS, Ogbuoji O, Schmidler GDS. Development and validation of DeciBHAL-US: A novel microsimulation model of hearing loss across the lifespan in the United States. EClinicalMedicine. 2022 Jan 13;44:101268. doi: 10.1016/j.eclinm.2021.101268https://repositorio.udd.cl/handle/11447/7376Background: Hearing loss affects over 50% of people in the US across their lifespan and there is a lack of decision modeling frameworks to inform optimal hearing healthcare delivery. Our objective was to develop and validate a microsimulation model of hearing loss across the lifespan in the US. Methods: We collaborated with the Lancet Commission on Hearing Loss to outline model structure, identify input data sources, and calibrate/validate DeciBHAL-US (Decision model of the Burden of Hearing loss Across the Lifespan). We populated the model with literature-based estimates and validated the conceptual model with key informants. We validated key model endpoints to the published literature, including: 1) natural history of sensorineural hearing loss (SNHL), 2) natural history of conductive hearing loss (CHL), and 3) the hearing loss cascade of care. We reported the coefficient of variance root mean square error (CV-RMSE), considering values ≤15% to indicate adequate fit. Findings: For SNHL prevalence, the CV-RMSE for model projected male and female age-specific prevalence compared to sex-adjusted National Health and Nutrition Examination Survey (NHANES) data was 4.9 and 5.7%, respectively. Incorporating literature-based age-related decline in SNHL, we validated mean four-frequency average hearing loss in the better ear (dB) among all persons to longitudinal data (CV-RMSE=11.3%). We validated the age-stratified prevalence of CHL to adjusted NHANES data (CV-RMSE=10.9%). We incorporated age- and severity-stratified time to first hearing aid (HA) use data and HA discontinuation data (adjusted for time-period of use) and validated to NHANES estimates on the prevalence of adult HA use (CV-RMSE=10.3%). Interpretation: Our results indicate adequate model fit to internal and external validation data. Future incorporation of cost and severity-stratified utility data will allow for cost-effectiveness analysis of US hearing healthcare interventions across the lifespan. Further research might expand the modeling framework to international settings.enHearing loss acrossUnited StatesArticlehttps://doi.org/10.1016/j.eclinm.2021.101268